Epitalon + MOTS-c Blend

How this combination works

The community rationale pairs two ageing-related mechanisms: Epitalon's reported telomerase activation and telomere elongation and MOTS-c's AMPK-mediated regulation of energy metabolism and mitochondrial biogenesis. Circulating MOTS-c declines with age. The pairing targets two separate hallmarks of ageing, but neither compound has demonstrated lifespan or healthspan benefit in human trials, and the combination is untested. This rationale is mechanistic inference only.

Combined mechanism

Epitalon induces expression of the telomerase catalytic subunit (hTERT), increases telomerase activity and extends telomere length in normal human somatic cells and cancer cell lines. A correction notice has been published for the 2025 telomere study. It also binds histones and DNA at specific sequences and may regulate gene transcription epigenetically. MOTS-c is encoded within the mitochondrial 12S rRNA gene. It inhibits the folate cycle and de novo purine biosynthesis, leading to AMPK activation. Under metabolic stress it moves to the nucleus and regulates antioxidant-response genes. Circulating levels decline with age. The two act on unrelated pathways (telomere maintenance vs mitochondrial–AMPK signalling). No human pharmacokinetic or pharmacodynamic data exist for the combination.

What each component does

Evidence base for this combination

No combo-specific RCTNo study testing Epitalon and MOTS-c together is cited in either compound's approved file (reviewed 2026-10-16). Any rationale for combining them is mechanistic inference from each compound studied on its own, not evidence that the combination works or is safe.

Safety considerations for this combination

• No combination-specific safety data exist for Epitalon + MOTS-c. The signals below come from each compound studied on its own. Component approved files
• Epitalon has been identified in illegal pharmaceutical preparations with assumed cancer, anti-aging, and retinitis pigmentosa indications, highlighting risks of unregulated supply and uncertain purity (PMID: 12535022). Inherited from Epitalon (PMID: 12535022)
• One 2026 review classified Epitalon as a 'non-approved peptide' lacking long-term safety data and systematic validation, in contrast to FDA-approved peptide agents (PMID: 35408963). Inherited from Epitalon (PMID: 35408963)
• A 2007 study reported that epitalon injection decreased antioxidant activity in rat serum and cerebral cortex while reducing LPO products, suggesting complex modulation of the redox system that warrants further characterization (PMID: 18239817). Inherited from Epitalon (PMID: 18239817)
• In vitro data suggest Epitalon can extend telomere length in cancer cell lines (via ALT activation), raising a theoretical question about effects in oncological contexts that requires further study (PMID: 40908429). Inherited from Epitalon (PMID: 40908429)
• MOTS-c's approved file lists no compound-specific safety signals. That reflects limited study, not established safety; see the MOTS-c peptide page. MOTS-c approved file

Contraindications

• Use with active or past malignancy has not been studied. Epitalon extended telomeres in cancer cell lines in vitro, which raises a theoretical concern in oncological contexts. Inherited from Epitalon (PMID: 40908429)
• No explicit contraindications are stated in the reviewed abstracts. The reviewed literature does not identify any population for whom Epitalon is formally contraindicated. Inherited from Epitalon (PMID: 40141333)
• Epitalon + MOTS-c has not been evaluated as a combination in any clinical trial. The lack of combination-specific contraindications reflects that absence of study, not established safety. No combination study cited in either component file

Related blends